GlassScriptPhysician profile
Jeffrey Bruce Toner
NPI 1174549661
$13,473.20
in general payments reported to CMS, 2019-2025
53 companies · $1,717 in 2025
The $1,717 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $1,501 · 2021: $2,682 · 2022: $2,264 · 2023: $2,310 · 2024: $1,881 · 2025: $1,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,794 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,793.77 |
| Education | $113.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,230.56 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,121.12 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $941.48 | 2019-2025 | |
| Abbvie INC. | $899.88 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $850.85 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $800.22 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $791.01 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $554.72 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $538.98 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Amgen INC. | $443.18 | 2019-2025 | Repatha, Otezla, Evenity |
| Actelion Pharmaceuticals US, INC. | $374.26 | 2021-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $300.13 | 2021-2025 | |
| Allergan, INC. | $240.89 | 2019-2020 | |
| Lundbeck LLC | $233.41 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.35 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Toner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.